Hamlet Pharma News Today

/PRNewswire/ -- DelveInsights Medical Second Opinion Market Insights report provides the current and forecast market analysis, individual leading medical...

/PRNewswire/ -- DelveInsights Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, bladder cancer...

Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1. The new production, at a larger scale, will be essential for future expansions of the clinical trial program in bla...

Lund, May 31, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections,  announces that Hamlet Pharma has secured the production of larger quantities of Alpha1H. The new batch will be essential to extend the clinical trial program in patients with bladder cancer.

The shareholders of Hamlet Pharma AB (publ) (“Hamlet Pharma” or the “Company”), reg. no. 556568-8958, are hereby invited to the extraordinary general meeting on Wednesday, 17 May 2023 at 14:00 at High Court Malmö, Malmöhusvägen 1, SE-211 18 Malmö, Sweden. Registration for the meeting will commence at 13:30.

This press release or the merger does not constitute an offer, either directly or indirectly in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States, or in any other jurisdiction where such offer under the laws and regulations of such relevant jurisdiction would be prohibited by applicable law. Shareholders who are not resident in Sweden and who wish to accept the proposed merger consideration must carry out closer investigations regarding t...

Hamlet Pharma, listed on Spotlight Stock Market, was awarded an EIC Accelerator grant of 2.2 M EURO in the highly competitive Horizon 2020 program. The EIC accelerator program supports individual small and medium enterprises, in particular start ups and spin out companies, to develop and scale up game changing innovations. At the end of January 2023, Hamlet Pharma filed the final report of the work supported by this grant.

Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H and its collaboration with Linnane Pharma, to define the potential of BAMLET as a drug candidate.

/PRNewswire/ -- DelveInsights Bladder Cancer Pipeline Insight 2022 report provides comprehensive global coverage of available, marketed, and pipeline...

/PRNewswire/ -- The "Global Bladder Cancer Drug Market (2021-2026) by Type, Treatment, Malignant Potential, Distribution, Geography, Competitive Analysis and...